Skip to main content

Table 3 Potential cancer-related EV biomarkers for SCLC diagnosis based on ROC analysis

From: Circulating microvesicles and exosomes in small cell lung cancer by quantitative proteomics

20 K SCLC|control

Protein

AUC

95% CI

p-value

Sensitivity (%)

Specificity (%)

Log2 FC

ILK

0.76

0.55–0.87

0.0192

75

59

1.0

ORM1

0.76

0.62–0.89

0.0021

79

54

1.0

GYPA

0.75

0.59–0.90

0.0092

77

64

1.0

QSOX1

0.79

0.63–0.94

0.0047

87

63

− 1.1

CA1

0.80

0.65–0.94

0.0011

83

74

− 1.2

PRDX2

0.73

0.58–0.88

0.0083

77

67

− 1.2

ANK1

0.76

0.55–0.96

0.0301

78

70

− 2.6

ITGA6

0.74

0.59–0.90

0.0084

59

83

− 2.6

SPTB

0.75

0.54–0.96

0.0419

63

80

− 2.7

SPTA1

0.81

0.65–0.98

0.0046

82

76

− 3.2

100 K SCLC|control

Protein

AUC

95% CI

p-value

Sensitivity (%)

Specificity (%)

Log2 FC

APOC2

0.81

0.65–1.0

0.0140

78

89

2.8

LRG1

0.84

0.72–0.96

0.0002

82

75

1.2

APOB

0.86

0.76–0.96

 < 0.0001

83

75

1.1

PRDX1

0.74

0.53–0.86

0.0407

89

50

− 1.0

OIT3

0.74

0.59–0.83

0.0058

76

65

− 1.2

  1. A Log2 FC ± 1 indicates a twofold increase (+) or decrease (−) in SCLC compared to controls.
  2. SCLC small cell lung cancer, AUC area under the curve, CI confidence interval, FC fold change, CA1 carbonic anhydrase 1, QSOX1 sulfhydryl oxidase 1, ILK integrin-linked protein kinase, ORM1 alpha-1-acid glycoprotein 1, ANK1 ankyrin-1, GYPA glycophorin-A, ITGA6 integrin alpha-2, PRDX2 peroxiredoxin-2, SPTB spectrin beta chain erythrocytic, SPTA1 Spectrin alpha chain erythrocytic 1, APOC2 Apolipoprotein C-II, LRG1 leucine-rich alpha-2-glycoprotein, APOB apolipoprotein B, PRDX1 peroxiredoxin-1, OIT3 oncoprotein-induced transcript 3 protein
Back to article page

Clinical Proteomics

ISSN: 1559-0275